Given a neoplasm of uncertain behavior of skin on a patient's face that is suspected to be a basal cell carcinoma (BCC), the typical first step is to perform a shave biopsy to determine the type of basal cell carcinomas so that one can decide the treatment {1}. Punch biopsies are also sometimes used instead of shave biopsies {2,3}.
Which criteria are used to choose whether to perform a shave biopsy or a punch biopsy to diagnose suspected facial basal cell carcinomas? (i.e., confirming whether it is a BCC and if so, determining which type of BCC it is).
References:
-
A skin biopsy is often required to confirm the diagnosis and determine the histologic subtype of basal cell carcinoma (BCC). Most often, a shave biopsy is all that is required. [Mar 2, 2020]
{2} https://www.apma.org/files/Derm-%20case%20reports%20APMA%202018.pdf (mirror)
{3} Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-up. David Vidal, MD, PhD; Xavier Matías-Guiu, MD, PhD; Agustín Alomar, MD, PhD. Arch Dermatol. 2007;143(2):264-276. https://doi.org/doi:10.1001/archderm.143.2.266
A 4-mm punch biopsy specimen was taken during the first 3 weeks of therapy to study the mechanism of action of imiquimod in BCC,2 and a final biopsy specimen was obtained 6 weeks after treatment to assess clearance of BCC.